RNA
Atrium Therapeutics, Inc.
7.90$
-0.8%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +9.7% | +51.4% | +41.6% | +21.8% | -4.7% | -6.7% | -6.2% | -79.7% | +0.3% | +5.0% | -4.1% | |
| – | +10.0% | +52.9% | +42.2% | +22.1% | -4.9% | -7.0% | -12.9% | -78.3% | +0.6% | +4.7% | -3.7% | |
| – | +116.1% | +154.7% | +22.1% | -35.7% | -40.6% | +15.6% | -4.1% | +10.7% | +0.0% | -0.8% | -72.9% | |
| – | +9.7% | +53.8% | +41.8% | +22.3% | -5.5% | -8.1% | -14.3% | -77.2% | +0.0% | -0.8% | -1.4% | |
| – | +762.3% | +4.8% | +73.8% | +22.2% | +46.9% | +29.6% | -76.7% | +76.1% | -17.3% | +20.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +129.4% | -5.6% | +4.8% | +8.7% | +1.1% | -6.2% | +35.2% | -63.3% | +9.9% | -18.0% | +13.2% | |
| – | +65.6% | -7.1% | +12.4% | +8.5% | +7.3% | -13.4% | +59.1% | -76.5% | +31.7% | -47.6% | +43.8% | |
| – | +1.0% | +2.4% | +1.0% | +1.0% | +1.1% | +1.0% | +1.1% | +1.1% | -7.4% | -27.0% | -37.2% | |
| – | +58.7% | -73.3% | +278.4% | -13.8% | +10.4% | -21.6% | -41.0% | -88.5% | +875.2% | -81.7% | +335.3% | |
| – | -3.2% | +65.9% | +47.0% | +23.1% | -5.2% | -6.8% | -10.2% | -82.2% | -2.6% | +12.9% | -8.3% | |
| – | – | – | – | – | – | – | – | – | – | – | -166.4% | |
| – | +2.6% | +14.7% | +22.6% | +15.4% | +4.2% | +0.6% | +0.3% | +6.4% | -87.6% | -0.1% | +0.0% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.